12:00 AM
Mar 29, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Zacutex lexipafant: Phase III

Zacutex did not meet its primary end point of a significant difference in the number of deaths observed within 28 days of treatment in 1,500 patients receiving...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >